Table 2.
Fecal immunochemical test performance by test cut-off.
| ≥10 μg/g (≥50 ng/mL) (N/%) |
≥15 μg/g (≥75 ng/mL) (N/%) |
≥20 μg/g (≥100 ng/mL) (N/%) |
≥40 μg/g (≥200 ng/mL) (N/%) |
≥100 μg/g (≥500 ng/mL) (N/%) |
|
|---|---|---|---|---|---|
| CRC | 449 (2.3) | 409 (3.1) | 388 (3.8) | 344 (5.7) | 242 (8.4) |
| Missed CRC | — | 40 (8.9) | 61 (13.6) | 105 (23.4) | 207 (46.1) |
| HRA | 4012 (20.4) | 3176 (24.4) | 2712 (26.9) | 1911 (31.6) | 1109 (38.4) |
| Missed HRA | — | 836 (20.8) | 1300 (32.4) | 2101 (52.4) | 2903 (72.4) |
| MLRA | 1173 (6.0) | 772 (5.9) | 584 (5.8) | 321 (5.3) | 132 (4.6) |
| LRA | 5029 (25.6) | 3172 (24.4) | 2359 (23.4) | 1247 (20.6) | 474 (16.4) |
| All neoplasia | 10663 (54.2) | 7529 (57.8) | 6043 (59.9) | 3823 (63.2) | 1957 (67.8) |
| CSPY saved | — | 6641 (33.8) | 9571 (48.7) | 13615 (69.3) | 16773 (85.3) |
| Total results | 19660 | 13019 | 10089 | 6045 | 2887 |
CRC, colorectal cancer; CSPY, colonoscopy; HRA, high-risk adenoma; LRA, low-risk adenoma; MLRA, multiple low-risk adenomas.